查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589343

失智症药物市场：依适应症、药物类别划分 - 2025-2030 年全球预测

Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年失智症药物市场价值为98亿美元，预计到2024年将达到107.8亿美元，复合年增长率为10.39%，到2030年将达到195.8亿美元。

失智症治疗药物市场范围主要包括旨在治疗和管理失智症相关症状的各种治疗方法，例如阿兹海默症、血管性失智症、路易氏体失智症和额颞叶治疗性介入。全球失智症盛行率不断上升，迫切需要提高意识并减轻失智症的社会和家庭负担，这推动了对这些药物的需求。最终用途主要是症状管理和减缓疾病进展，包括医院、诊所和专科护理中心。市场成长受到人口老化、生技进步和研发投资增加等因素的影响。此外，政府措施和医疗保健基础设施发展是市场扩张的催化剂。最近的潜在商机包括开发针对潜在病理过程的疾病修正治疗，例如Tau和 β-淀粉样蛋白积累，以及旨在支持认知復健的新数位疗法。为了利用这些机会，鼓励相关人员投资个人化医疗方法并在药物开发中利用人工智慧技术。然而，市场开拓面临药物开发高成本、监管核准流程冗长以及失智症异质性导致的临床试验设计挑战等限制。此外，现有治疗方法的安全性和有效性问题也构成了障碍。克服这些挑战需要学术界、工业界和监管机构之间的密切合作。潜在的创新领域包括早期检测的生物标记研究、与药物治疗相结合的非药物干预以及探索肠脑轴作为新的治疗标靶。市场的本质是动态和竞争的，其特点是技术的快速进步和对以患者为中心的护理的日益重视。为了取得成功，公司应优先考虑适应性，继续探索未满足的需求，并扩大伙伴关係，以培育失智症管理的全人解决方案。

主要市场统计
基准年[2023] 98亿美元
预测年份 [2024] 107.8亿美元
预测年份 [2030] 195.8亿美元
复合年增长率（%） 10.39%

市场动态：揭示快速发展的失智症药物市场的关键市场洞察

供需的动态交互作用正在改变失智症治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加
    • 阿兹海默症率增加
    • 政府对阿兹海默症的资助和宣传计划
  • 市场限制因素
    • 研发成本上升
  • 市场机会
    • 透过提供安全可靠的药品，线上药局服务持续受欢迎
    • 新药和治疗方法的进展
    • 透过阿兹海默症和相关失智症治疗方法和生物标记开发的进步创造资金筹措机会
  • 市场挑战
    • 病理和发病机转复杂，缺乏早期检测的生物标记

波特五力：驾驭失智症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解失智症治疗市场的外在影响

外部宏观环境因素在塑造失智症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解失智症治疗药物市场的竞争状况

失智症治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 失智症药物市场定位失智症供应商绩效评估

FPNV 定位矩阵是评估失智症治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘失智症治疗市场的成功之路

失智症治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化加剧
      • 阿兹海默症的发生率增加
      • 政府对阿兹海默症的资助和宣传计划
    • 抑制因素
      • 研究和药物开发成本高
    • 机会
      • 透过提供安全可靠的药品，线上药局服务持续受欢迎。
      • 新药和治疗方法的进展
      • 推动阿兹海默症和相关失智症的治疗方法和生物标记的开发创造了资金筹措机会。
    • 任务
      • 病理学和发病机制复杂，并且没有用于早期检测该疾病的生物标记。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依适应症分類的失智症治疗药物市场

  • 阿兹海默症
  • 路易氏体失智症
  • 帕金森氏症失智症
  • 血管失智症

第七章依药物类别分類的失智症治疗药物市场

  • 胆碱酯酶抑制剂
  • 麸胺酸抑制剂
  • 单胺氧化酶抑制剂

第八章北美和南美失智症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区失智症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的失智症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Anavex Life Sciences Corp.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Quidel Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Zydus Cadila
Product Code: MRR-FD3F12D54013

The Dementia Drugs Market was valued at USD 9.80 billion in 2023, expected to reach USD 10.78 billion in 2024, and is projected to grow at a CAGR of 10.39%, to USD 19.58 billion by 2030.

The scope of the dementia drugs market encompasses various therapeutic interventions designed to treat and manage symptoms associated with dementia, mainly Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal disorders. The necessity of these drugs is driven by the increasing prevalence of dementia globally, heightened awareness, and the urgent need to alleviate the societal and familial burdens of the disease. Applications primarily include symptom management and slowing disease progression, with end-use markets involving hospitals, clinics, and specialized care centers. Market growth is influenced by factors such as an aging population, advancements in biotechnology, and increased R&D investments. Furthermore, governmental initiatives and supportive healthcare infrastructure serve as catalysts for market expansion. Recent potential opportunities include the development of disease-modifying therapies that target underlying pathological processes, such as tau and beta-amyloid accumulations, as well as emerging digital therapeutics aiming to support cognitive rehabilitation. To capitalize on these opportunities, stakeholders are encouraged to invest in personalized medicine approaches and leverage AI technologies in drug development. However, the market faces limitations like high costs of drug development, lengthy regulatory approval processes, and challenges in clinical trial designs due to the heterogeneous nature of dementia. Moreover, safety and efficacy concerns regarding existing treatments present obstacles. Overcoming these challenges requires strong collaboration between academia, industry, and regulatory bodies. Potential areas for innovation include biomarker research for early detection, non-pharmacological interventions paired with pharmacotherapy, and exploring the gut-brain axis as a novel therapeutic target. The nature of the market is dynamic and competitive, characterized by rapid technological advancements and a growing emphasis on patient-centric care. To thrive, companies should prioritize adaptability, continue exploring unmet needs, and expand partnerships to foster holistic solutions for dementia management.

KEY MARKET STATISTICS
Base Year [2023] USD 9.80 billion
Estimated Year [2024] USD 10.78 billion
Forecast Year [2030] USD 19.58 billion
CAGR (%) 10.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dementia Drugs Market

The Dementia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population base
    • Increase in prevalence of Alzheimer disease
    • Government funding & awareness programs for Alzheimer disease
  • Market Restraints
    • High costs of research and drug development
  • Market Opportunities
    • Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
    • Advancement of new drugs and treatments
    • Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
  • Market Challenges
    • Complex pathology and etiology and no biomarkers for early detection of the disease

Porter's Five Forces: A Strategic Tool for Navigating the Dementia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dementia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dementia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dementia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dementia Drugs Market

A detailed market share analysis in the Dementia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dementia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dementia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dementia Drugs Market

A strategic analysis of the Dementia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dementia Drugs Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., AstraZeneca PLC, Aurobindo Pharma Limited, Biogen Inc., Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Quidel Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indications, market is studied across Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, and Vascular Dementia.
  • Based on Drug Class, market is studied across Cholinesterase Inhibitors, Glutamate Inhibitors, and MAO Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population base
      • 5.1.1.2. Increase in prevalence of Alzheimer disease
      • 5.1.1.3. Government funding & awareness programs for Alzheimer disease
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of research and drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
      • 5.1.3.2. Advancement of new drugs and treatments
      • 5.1.3.3. Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex pathology and etiology and no biomarkers for early detection of the disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dementia Drugs Market, by Indications

  • 6.1. Introduction
  • 6.2. Alzheimer's Disease
  • 6.3. Lewy Body Dementia
  • 6.4. Parkinsons Disease Dementia
  • 6.5. Vascular Dementia

7. Dementia Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Cholinesterase Inhibitors
  • 7.3. Glutamate Inhibitors
  • 7.4. MAO Inhibitors

8. Americas Dementia Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dementia Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dementia Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anavex Life Sciences Corp.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Biogen Inc.
  • 5. Eisai Co., Ltd
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. Forest Laboratories, Inc.
  • 9. Janssen Global Services, LLC
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Pfizer, Inc.
  • 13. Quidel Corporation
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Valeant Pharmaceuticals International, Inc.
  • 17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DEMENTIA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DEMENTIA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PARKINSONS DISEASE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MAO INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023